| ESVCP – European Society of Veterinary Clinical Pathology |
| Wednesday 1 September |
| 14.40 |
ESVCP-O-1 |
Cerná |
Platelet indices and their dynamics in dogs with systemic inflammatory response syndrome - prospective study |
| 14.55 |
ESVCP-O-3 |
Bech |
Reticulated platelets and Nucleic Acid Containing Units (NACU) in dogs with cancer |
| 15.10 |
ESVCP-O-4 |
Rompf |
Biological variation of plasma procalcitonin in clinically healthy dogs |
| 15.25 |
ESVCP-O-5 |
Ruíz-Tapia |
Urinary C reactive protein in dogs with chronic kidney disease: preliminary study |
| 15.40 |
ESVCP-O-6 |
Zoia |
A simple prognostic score identifying mortality in canine immune-mediated haemolytic anaemia (IMHA) |
| 16.30 |
ESVCP-O-7 |
Broadbridge |
Can we use urine pH or the haem dipstick result to predict bacteriuria in cats and dogs with inactive urine sediments? |
| ESVCN – European Society of Veterinary Comparative Nutrition |
| Wednesday 1 September |
| 12.05 |
ESVCN-O-1 |
Steffen |
High intake of sodium chloride for 28 days causes no effect on serum FGF-23 concentrations in cats |
| 12.20 |
ESVCN-O-2 |
Andersson |
Exploration of body weight in 115 000 young adult dogs of 72 breeds |
| 12.35 |
ESVCN-O-3 |
German |
Beyond the scale: a retrospective observational study of cats and dogs presenting to a referral centre with severe obesity |
| ESVIM – European Society of Veterinary Internal Medicine |
| Wednesday 1 September |
| 08.00 |
ESVIM-O-1 |
Lebastard |
Association between bronchoalveolar lavage fluid quantitative bacterial culture results and antibiotic requirement in dogs with lower respiratory tract signs |
| 08.15 |
ESVIM-O-2 |
Gareis |
Evaluation of pulmonary function by whole-body plethysmography for therapy monitoring in cats with chronic bronchial disease |
| 08.30 |
ESVIM-O-3 |
Fastrès |
Serum and bronchoalveolar lavage fluid concentration of osteopontin and fibronectin in West Highland white terriers either affected with canine idiopathic pulmonary fibrosis or healthy and other terriers non predisposed to the disease |
| 09.00 |
ESVIM-O-4 |
Carluen |
Incidence and characterization of penetration and aspiration in dogs using videofluoroscopic swallow studies |
| 09.15 |
ESVIM-O-5 |
Rodrigues |
Antimicrobial discontinuation in dogs with acute aspiration pneumonia based on normal C-Reactive Protein and clinical improvement |
| 09.30 |
ESVIM-O-6 |
Machiels |
Study of the use of IDEXX PROCYTE for total and differential cellular counts of bronchoalveolar lavage fluid in healthy dogs |
| 09.45 |
ESVIM-O-7 |
Kouki |
Bile acids in saliva of dogs with respiratory diseases and of healthy dogs pre- and post-feeding |
| 10.00 |
ESVIM-O-8 |
Biénès |
Effect of bronchoalveolar lavage on lung ultrasound and radiography in healthy dogs |
| 10.15 |
ESVIM-O-9 |
Lyssens |
Gentamicin concentrations in bronchoalveolar lavage and serum in healthy dogs after inhalation therapy |
| 10.30 |
ESVIM-O-10 |
Biénès |
Gentamicin concentration in nasal lavage in healthy dogs after inhalation therapy |
| 11.20 |
ESVIM-O-11 |
Vangrinsven |
Comparison of culture- dependent and -independent methods on nasal swabs in dogs with nasal discharge |
| 11.35 |
ESVIM-O-12 |
Vangrinsven |
Alterations of the nasal microbiota in dogs with sinonasal aspergillosis before and after cure and comparison with chronic idiopathic rhinitis |
| 11.50 |
ESVIM-O-13 |
Idalan |
Comparison of immunohematological diagnostic tests including six different Coombs’ test methods in dogs suspected to have immune-mediated hemolytic anemia |
| 12.05 |
ESVIM-O-14 |
Bouzouraa |
Diagnostic utility of C-reactive protein on plasma and abdominal fluid in dogs with ascites |
| 12.20 |
ESVIM-O-15 |
Work |
Shar Pei auto-inflammatory disorder (SPAID) in the United Kingdom - a retrospective survey |
| 12.35 |
ESVIM-O-16 |
Broughton |
Diagnoses and outcomes associated with ionised hypercalcaemia in a referral population of cats |
| Thursday 2 September |
| 08.00 |
ESVIM-O-17 |
Tumbarello |
A prospective randomized trial of methylprednisolone with or without cyclosporine or mycophenolate mofetil for the treatment of immune-mediated haemolytic anaemia in 43 dogs |
| 08.15 |
ESVIM-O-18 |
Moretto |
Suspected hypertensive encephalopathy in cats with systemic hypertension |
| 08.30 |
ESVIM-O-19 |
Lamminen |
Pregabalin alleviates feline anxiety and fear during transport and veterinary visits – a clinical field study |
| 08.45 |
ESVIM-O-20 |
Bunn |
Prevalence and causes of fasting hypertriglyceridaemia in Australian Miniature Schnauzers |
| ISCAID - International Society for Companion Animal Infectious Diseases |
| Thursday 2 September |
| 14.15 |
ISCAID-O-1 |
Schwedinger |
Results of a study about vaccination decision of dog owners |
| 14.30 |
ISCAID-O-2 |
Jähne |
Detection of mutated and non-mutated feline coronaviruses in cats without feline infectious peritonitis |
| 14.45 |
ISCAID-O-3 |
Krafft |
Report of one year surveillance of SARS-CoV-2 detection by PCR in dogs and cats with various exposure risk |
| 15.00 |
ISCAID-O-4 |
Walter-Weingärtner |
Comparison of eight commercially available point-of-care tests to detect canine parvovirus in faeces of dogs |
| 15.15 |
ISCAID-O-5 |
Spiri |
Modified-live FCV vaccination reduces viral RNA loads, duration of RNAemia and the severity of clinical signs after heterologous FCV Challenge |
| 15.30 |
ISCAID-O-6 |
Vahlenkamp |
High prevalence of antibodies against feline morbillivirus type 1 and 2 and association with FLUTD and increased blood creatinine concentrations in domestic cats |
| 15.45 |
ISCAID-O-7 |
Griebsch |
Emerging canine leptospirosis in NSW, Australia |
| 16.00 |
ISCAID-O-8 |
Rigo |
Experimental infection by leptospira australis in cats |
| 16.30 |
ISCAID-O-9 |
Taylor |
Exploration of the role of Leptospira spp. in cats with chronic kidney disease (CKD) |
| 16.45 |
ISCAID-O-10 |
Bouzouraa |
Epidemiological, clinical and biological impact of hemoplasmas in cancer-bearing dogs: A case-control study on 324 cases |
| 17.00 |
ISCAID-O-11 |
Schmitt |
Dissemination of blaOXA-48 carbapenemase- and extended-spectrum beta-lactamase-producing Enterobacteriaceae in a Swiss companion animal clinic |
| 17.15 |
ISCAID-O-12 |
Steffensen |
Methylprednisolone induces neutrophil extracellular trap formation and enhances bactericidal effect of canine neutrophils |
| 17.30 |
ISCAID-O-13 |
McCartin |
Evaluation of serum 25-hydroxyvitamin D and C-reactive protein as biomarkers in dogs with coccidioidomycosis |
| 17.45 |
ISCAID-O-14 |
Willi |
Expanded geographic occurrence of Cytauxzoon sp. infection in domestic cats in Switzerland and detection of the infection in felid samples collected two decades ago |
| 18.00 |
ISCAID-O-15 |
Gentil |
Prevalence of Taeniidae eggs and Echinococcus multilocularis in faecal samples of dogs in Europe |
| SCH – Society of Comparative Hepatology |
| Thursday 2 September |
| 11.05 |
SCH-O-1 |
Dröes |
Prevalence of portal vein thrombosis in 153 dogs with chronic hepatitis: 2009-2019 |
| 11.20 |
SCH-O-2 |
Yamkate |
Immunohistochemical expression of caspase-3 and malondialdehyde in archived liver specimens from dogs with chronic hepatitis |
| 11.35 |
SCH-O-3 |
Brunero |
Investigation of risk factors for gallbladder mucocoele development in Border Terriers; a UK-based, online owner survey |
| 11.50 |
SCH-O-4 |
Jaffey |
Clinical findings and prognostic variables in dogs from Asia with gallbladder mucocele |
| 12.05 |
SCH-O-5 |
Phillips |
Dogs with congenial portosystemic shunts have altered amino acid profiles compared to healthy dogs |
| 12.20 |
SCH-O-6 |
Devriendt |
Plasma amino acid profiles in dogs with closed extrahepatic portosystemic shunts improve but remain abnormal three months after successful gradual attenuation |
| 12.35 |
SCH-O-7 |
Devriendt |
Serum vitamin concentrations suggest incomplete restoration of liver function three months after successful gradual attenuation of extrahepatic shunts in dogs |
| ESVC – European Society of Veterinary Cardiology |
| Thursday 2 September |
| 09.15 |
ESVC-O-1 |
Bagardi |
Circulating miRNAs as potential biomarkers of early myxomatous mitral valve disease in Cavalier King Charles Spaniels |
| 09.30 |
ESVC-O-2 |
Wesselowski |
Use of physical examination, electrocardiography, radiography and biomarkers to predict stage B2 myxomatous mitral valve disease in preclinical Cavalier King Charles Spaniels |
| 09.45 |
ESVC-O-3 |
Grosso |
Prognostic significance of different echocardiographic parameters of left atrial size in dogs with asymptomatic myxomatous mitral valve disease |
| 10.00 |
ESVC-O-4 |
Partington |
The effect of obesity and subsequent weight loss on cardiac structure and function in dogs |
| 10.15 |
ESVC-O-5 |
Safian |
Performance of different echocardiographic measurements of left atrial size by observers with different levels of experience |
| 11.20 |
ESVC-O-6 |
Hezzell |
Teaching vets to be EPIC: validation of a focussed echocardiographic training program for general practitioners - the FEET-FIRST Study |
| 11.35 |
ESVC-O-7 |
Giraud |
Evaluation of point-of-care ultrasound performed by non-cardiologists for diagnosis of degenerative mitral valve disease in dogs presented to the cardiology service |
| 11.50 |
ESVC-O-8 |
Saponaro |
A new auscultatory finding confirmed by phonocardiography in cats with obstructive hypertrophic cardiomyopathy |
| Friday 3 September |
| 09.15 |
ESVC-O-9 |
Malcolm |
Reproducibility and repeatability of radiographic measurements of cardiac size in dogs |
| 09.30 |
ESVC-O-11 |
Kuo |
An international survey of preferences for echocardiographic assessment of left atrial size in dogs: The BENEFIT Project |
| 09.45 |
ESVC-O-12 |
Lekane |
Left Ventricular Eccentricity index for assessment of precapillary pulmonary hypertension in dogs |
| 10.00 |
ESVC-O-13 |
Oliveira |
Continuous heart rate monitoring by Holter and validation of heart rate spot-checks to measure circadian variation in heart rate in dogs with atrial fibrillation |
| 10.15 |
ESVC-O-14 |
Saponaro |
Holter characterization of ventricular and supraventricular arrhythmia in English bulldogs with presumed arrhythmogenic cardiomyopathy before specific antiarrhythmic therapy (94 cases) |
| 11.20 |
ESVC-O-15 |
Ward |
Renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy |
| 11.35 |
ESVC-O-16 |
Fidanzio |
Effect of the sampling time on urinary electrolytes following furosemide administration in dogs with myxomatous mitral valve disease |
| 11.50 |
ESVC-O-17 |
Patata |
Echocardiographic variables predictive of clinical signs in dogs with pulmonary stenosis |
| 12.05 |
ESVC-O-18 |
Nisini |
Bioelectrical Impedance Analysis in dogs with right congestive heart failure before and after treatment: a pilot study |
| 12.20 |
ESVC-O-19 |
Reimann |
Platelet aggregation response to pimobendan in Cavalier King Charles Spaniels with myxomatous mitral valve disease |
| 12.35 |
ESVC-O-20 |
Franchini |
The Longitudinal Outcome Of Canine (K9) myxomatous mitral valve disease (LOOK-Mitral) registry: baseline treatment characteristics |
| ESCG – European Society of Comparative Gastroenterology |
| Friday 3 September |
| 14.25 |
ESCG-O-1 |
Bernard |
Comparative analysis of the distribution and severity of the lesions within the digestive tract in feline low-grade intestinal T-cell lymphoma or lymphoplasmacytic enteritis |
| 14.40 |
ESCG-O-2 |
Da Riz |
Short-term survival and associated factors after surgical intestinal biopsies in cats with chronic enteropathy |
| 14.55 |
ESCG-O-3 |
Wu |
Identification of bacteria in pancreas, liver, and bile of apparently healthy cats using next generation 16S rRNA sequencing and standard bacteriological culture |
| 15.10 |
ESCG-O-4 |
Collier |
Investigating fecal microbial transplant in dogs with inflammatory bowel disease: a pilot study |
| 15.25 |
ESCG-O-5 |
Toresson |
Clinical effects of fecal microbiota transplantation in dogs with chronic enteropathy |
| 15.40 |
ESCG-O-6 |
Kuijlaars |
Faecal bile acid profiles in dogs with chronic enteropathies versus healthy controls |
| 15.55 |
ESCG-O-7 |
Sung |
Fecal fatty acid, cholesterol, and bile acid concentrations in cats with chronic enteropathy |
| 16.30 |
ESCG-O-8 |
Walker |
Metabolomic serum profiling in dogs with chronic enteropathy |
| 16.45 |
ESCG-O-9 |
Csukovich |
Taking the next step: Modelling infectious diseases in canine intestinal organoids |
| 17.00 |
ESCG-O-10 |
Thomson |
Retrospective analysis of the association between hepatic pathology and DGGR lipase in canines with histologically normal pancreas |
| 17.15 |
ESCG-O-11 |
Méric |
Colorectal polypoid masses in dogs: multicentre retrospective study of 53 cases |
| 17.30 |
ESCG-O-12 |
Dupont |
Suspected acute hemorrhagic diarrhea syndrome in out-patients: A preliminary study of disease severity, treatment, outcome and client satisfaction |
| 17.45 |
ESCG-O-13 |
Tamura |
Low-dose oral cobalamin supplementation ameliorated in serum cobalamin concentrations in dogs with chronic enteropathy when compared with small cell gastrointestinal lymphoma |
| 18.00 |
ESCG-O-14 |
Muradas |
Assessment of visceral pain in dogs with chronic enteropathy and its’ effect on behaviour and owner-observed quality of life |
| ESVNU – European Society of Veterinary Nephrology and Urology |
| Friday 3 September |
| 09.45 |
ESVNU-O-1 |
Kongtasai |
Urinary liver-type fatty acid-binding protein in cats with International Renal Interest Society (IRIS) stage 1 chronic kidney disease within a healthy elderly cohort |
| 10.00 |
ESVNU-O-2 |
Tang |
Risk factors and implications associated with renal mineralisation in feline chronic kidney disease (CKD) |
| 10.15 |
ESVNU-O-3 |
Lippi |
Erythrogram patterns in chronic kidney disease of dogs |
| 11.20 |
ESVNU-O-4 |
Scarpa |
Evaluation of the clinical efficacy of benazepril in the treatment of renal proteinuria in dogs |
| 11.35 |
ESVNU-O-5 |
Rimer |
Acute kidney injury in dogs: Etiology, clinical and clinicopathologic findings, prognostic markers, and outcome |
| 11.50 |
ESVNU-O-6 |
Brans |
Effect of storage conditions and measurement device on serum Symmetric dimethylarginine in cats and dogs |
| 12.05 |
ESVNU-O-7 |
Harrer |
Bacterial urinary tract infection and subclinical bacteriuria in dogs receiving chemotherapy: a prospective observational longitudinal clinical study |
| 12.20- |
ESVNU-O-8 |
Amram |
Measurement of the delivered dialysis dose of intermittent low-efficiency hemodiafiltration in dogs with acute kidney injury. |
| 12.35 |
ESVNU-O-9 |
Duperrier-Simond |
Occurrence of cardio-vascular events in cats with acute urinary tract obstruction |
| ESVE – European Society of Veterinary Endocrinology |
| Saturday 4 September |
| 08.15 |
ESVE-O-1 |
Tardo |
Prospective evaluation of the prevalence of eunatraemic, eukalaemic hypoadrenocorticism in dogs with chronic gastrointestinal signs and risk of misdiagnosis in dogs with previous glucocorticoid administration |
| 08.30 |
ESVE-O-2 |
Aguiar |
Development and characterisation of feline thyroid organoids as an in vitro model for feline hyperthyroidism research |
| 08.45 |
ESVE-O-3 |
Scheemaeker |
Organoids of canine medullary thyroid carcinoma and feline thyroid adenomatous hyperplasia |
| 09.00 |
ESVE-O-4 |
Bree |
Multicentre retrospective review of clinical features and short-term follow-up of 110 cases of canine primary hypoparathyroidism |
| 09.15 |
ESVE-O-5 |
Corsini |
A prediction tool for diagnosis of canine hypothyroidism in clinical practice |
| 09.30 |
ESVE-O-6 |
Carvalho |
Diagnosis of naturally-occuring hypercortisolism by primary care veterinarians: a western European survey |
| 09.45 |
ESVE-O-7 |
Bunn |
Association of proteinuria with fasting hypertriglyceridaemia and hyperadrenocorticism in Australian Miniature Schnauzers |
| 10.00 |
ESVE-O-8 |
Schofield |
Role of internal medicine specialists in disseminating the evolving evidence base on Cushing’s syndrome |
| 10.15 |
ESVE-O-9 |
Da Riz |
Fibroblast Growth Factor-23 and phosphate metabolism in dogs with spontaneous hyperadrenocorticism (HAC) |
| 11.05 |
ESVE-O-10 |
Golinelli |
Evaluation of clinical, ultrasonographic, and clinicopathological findings in dogs with pituitary-dependent hypercortisolism and poor trilostane response |
| 11.20 |
ESVE-O-11 |
Rapastella |
Outcome in dogs with and without hyperadrenocorticism undergoing radiotherapy for pituitary macroadenomas |
| 11.35 |
ESVE-O-12 |
Miceli |
Cabergoline treatment for feline hypersomatotropism |
| 11.50 |
ESVE-O-13 |
Callegari |
Proteomic analysis in serum of cats with diabetes mellitus |
| 12.05 |
ESVE-O-14 |
Nivy |
Effect of periodontal treatment on glycemic control in canine diabetic patients: a prospective, clinical study |
| 12.20 |
ESVE-O-15 |
del Baldo |
the usefulness of different freestyle libre-derived metrics in assessing glycemic control in diabetic dogs |
| 12.35 |
ESVE-O-16 |
Jaffey |
Effects of calcitriol on leukocyte cytokine production in dogs with diabetes mellitus |
| ESVONC – European Society of Veterinary Oncology |
| Saturday 4 September |
| 09.15 |
ESVONC-O-1 |
Troedson |
Change of feline injection site sarcoma incidence and localization within the last 30 years |
| 09.30 |
ESVONC-O-2 |
Chalfon |
An update on environmental risk factors for the development of feline oral squamous cell carcinoma |
| 09.45 |
ESVONC-O-3 |
Faroni |
Possible association between anesthesia and recurrence in dogs with medium/large B-cell lymphoma in complete remission after chemo – immunotherapy |
| 10.00 |
ESVONC-O-4 |
Gedon |
BRAF mutation status and its prognostic significance in 79 canine urothelial carcinomas: a retrospective study (2006-2019) |
| 10.15 |
ESVONC-O-5 |
Williams |
The diagnostic utility of the neutrophil to lymphocyte ratio when investigating splenic masses in dogs |
| 11.20 |
ESVONC-O-6 |
Mason |
Outcomes of Dogs with Anal Sac Gland Carcinoma Treated With Surgery and Adjunctive Radiotherapy in Ten 3.6Gy Fractions |
| 11.35 |
ESVONC-O-7 |
Kritsotalaki |
Evaluation of outcome and toxicity in dogs undergoing “quad shot” radiation therapy for anal gland adenocarcinoma: a single center retrospective study of 17 cases |
| 11.50 |
ESVONC-O-8 |
Lappalainen |
High–grade feline gastrointestinal lymphoma in 43 cases: one treatment does not fit them all |
| 12.05 |
ESVONC-O-9 |
Marconato |
A phase 2, single-arm, open-label clinical trial on adjuvant active immunotherapy in dogs with appendicular osteosarcoma undergoing amputation and chemotherapy |
| 12.20 |
ESVONC-O-10 |
Busser |
Impact of a 10% dose reduction and length of treatment delays in the management of chemotherapy-induced neutropenia in dogs: a single-centre experience |
| 12.35 |
ESVONC-O-11 |
Chavalle |
Pharmacokinetic study of doxorubicin in cancer-bearing dogs: validation of a simple high-performance liquid chromatography (HPLC) method in 10 dogs |
